NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Price, News & Analysis $4.33 -0.04 (-0.92%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.27 -0.06 (-1.39%) As of 07/25/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About COMPASS Pathways Stock (NASDAQ:CMPS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COMPASS Pathways alerts:Sign Up Key Stats Today's Range$4.18▼$4.4150-Day Range$2.35▼$4.8052-Week Range$2.25▼$8.54Volume1.07 million shsAverage Volume2.47 million shsMarket Capitalization$405.11 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingModerate Buy Company Overview COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. Read More COMPASS Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCMPS MarketRank™: COMPASS Pathways scored higher than 35% of companies evaluated by MarketBeat, and ranked 758th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCOMPASS Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 3 research reports in the past 90 days.Read more about COMPASS Pathways' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for COMPASS Pathways are expected to grow in the coming year, from ($2.33) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about COMPASS Pathways' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.56% of the float of COMPASS Pathways has been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 79.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.56% of the float of COMPASS Pathways has been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 79.40%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.14 News SentimentCOMPASS Pathways has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for COMPASS Pathways this week, compared to 3 articles on an average week.Search Interest14 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows7 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.93% of the stock of COMPASS Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about COMPASS Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPS Stock News HeadlinesThese 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?July 20, 2025 | fool.comHC Wainwright Issues Negative Estimate for CMPS EarningsJuly 19, 2025 | americanbankingnews.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world. | Traders Agency (Ad)Brokers Set Expectations for CMPS Q1 EarningsJuly 18, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS)July 18, 2025 | americanbankingnews.comCathie Wood’s ARK Adds 125K COMPASS Pathways plc (CMPS) SharesJuly 15, 2025 | msn.comCOMPASS Pathways (CMPS) Upgraded to Buy: Here's Why - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comCompass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ETJuly 10, 2025 | businesswire.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? COMPASS Pathways' stock was trading at $3.78 at the beginning of 2025. Since then, CMPS shares have increased by 14.6% and is now trading at $4.33. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.03. Read the conference call transcript. When did COMPASS Pathways IPO? COMPASS Pathways (CMPS) raised $100 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that COMPASS Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings5/08/2025Today7/26/2025Next Earnings (Estimated)7/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for COMPASS Pathways$17.00 High Price Target$45.00 Low Price Target$6.00 Potential Upside/Downside+292.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$155.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.75% Return on Assets-59.42% Debt Debt-to-Equity Ratio0.11 Current Ratio10.18 Quick Ratio10.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book1.92Miscellaneous Outstanding Shares93,562,000Free Float89,885,000Market Cap$405.12 million OptionableOptionable Beta2.12 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CMPS) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.